- Home
- LQDA vs PRGS Comparison
LQDA vs PRGS Comparison
Compare LQDA & PRGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LQDA
- PRGS
- Stock Information
- Founded
- LQDA 2004
- PRGS 1981
- Country
- LQDA United States
- PRGS United States
- Employees
- LQDA N/A
- PRGS N/A
- Industry
- LQDA Biotechnology: Pharmaceutical Preparations
- PRGS Computer Software: Prepackaged Software
- Sector
- LQDA Health Care
- PRGS Technology
- Exchange
- LQDA Nasdaq
- PRGS Nasdaq
- Market Cap
- LQDA 1.7B
- PRGS 2.0B
- IPO Year
- LQDA 2018
- PRGS 1991
- Fundamental
- Price
- LQDA $25.95
- PRGS $45.73
- Analyst Decision
- LQDA Strong Buy
- PRGS Buy
- Analyst Count
- LQDA 10
- PRGS 7
- Target Price
- LQDA $31.40
- PRGS $72.86
- AVG Volume (30 Days)
- LQDA 3.4M
- PRGS 896.5K
- Earning Date
- LQDA 08-12-2025
- PRGS 09-23-2025
- Dividend Yield
- LQDA N/A
- PRGS 0.38%
- EPS Growth
- LQDA N/A
- PRGS N/A
- EPS
- LQDA N/A
- PRGS 1.30
- Revenue
- LQDA $19,322,000.00
- PRGS $869,017,000.00
- Revenue This Year
- LQDA $190.73
- PRGS $30.95
- Revenue Next Year
- LQDA $421.01
- PRGS $1.77
- P/E Ratio
- LQDA N/A
- PRGS $35.17
- Revenue Growth
- LQDA 30.20
- PRGS 22.10
- 52 Week Low
- LQDA $8.26
- PRGS $42.88
- 52 Week High
- LQDA $26.65
- PRGS $70.56
- Technical
- Relative Strength Index (RSI)
- LQDA 79.56
- PRGS 40.23
- Support Level
- LQDA $19.02
- PRGS $43.12
- Resistance Level
- LQDA $26.65
- PRGS $46.45
- Average True Range (ATR)
- LQDA 1.53
- PRGS 1.43
- MACD
- LQDA 0.64
- PRGS 0.37
- Stochastic Oscillator
- LQDA 92.88
- PRGS 40.08
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
About PRGS Progress Software Corporation (DE)
Progress Software Corporation provides software operate in one operating segment: software products for the development, deployment, and management of responsible, AI-powered applications and digital experiences. Following are products: Chef, Corticon, Data Direct, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, WhatsUp Gold. Geographical regions include United States, Canada, EMEA, Latin America, and Asia Pacific.